BioNTech SE (BNTX)
Chart Events
Performance Outlook
| Previous Close | 198.02 |
| Open | 196.65 |
| Bid | 195.82 x 800 |
| Ask | 196.66 x 1100 |
| Day's Range | 191.04 - 198.19 |
| 52 Week Range | 45.08 - 213.15 |
| Volume | 668,013 |
| Avg. Volume | 2,589,960 |
| Market Cap | 46.565B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 172.65 |
Fair Value
Related Research
- Motley Fool
Why Novavax Could Beat Moderna in Europe After Pfizer's Huge EU Vaccine Deal
The European Commission president has provided some hints that a supply agreement with Novavax could be on the way.
- Reuters
UPDATE 3-Pfizer seeks UK approval for use of COVID-19 vaccine in teenagers
Pfizer is seeking British approval for the use of its COVID-19 vaccine among 12- to 15-year olds and has submitted data to the health regulator, a company representative said on Tuesday, paving the way for inoculation of adolescents in the country. The vaccine, developed along with Germany's BioNTech , has already been approved in the United States and Canada for use against COVID-19 infections in children and young adults. "I can confirm we've submitted data on the efficacy of the vaccine in 12 to 15 year olds for review by U.K. MHRA," an official for the U.S. drugmaker told Reuters, referring to the Medicines and Healthcare products Regulatory Agency.
- Motley Fool
BioNTech Is No Longer a Buy, Says Analyst
Despite some good news recently about the coronavirus vaccine it co-developed, BioNTech (NASDAQ: BNTX) has been hit with a recommendation downgrade. In a research note published on Tuesday, Bryan Garnier analyst Olga Smolentseva changed her view on the stock to neutral from the previous buy recommendation. At the same time, though, she significantly raised her price target on the stock, from $135 per share to $206.
